Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Completed · Phase 2
Conditions studied: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
In brief
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with progressive metastatic transitional cell cancer of the urothelium.
Key facts
- Study ID
- NCT00397488
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 78
- Starts
- 2006-09-01
- Expected to finish
- 2012-02-01
- Last updated by the study team
- 2016-01-25
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.